Related Experiment Video
Updated: Jul 2, 2026
High-Density Lipoprotein-Specific Phospholipid Efflux Assay
Published on: September 30, 2025
Accuracy of analyses for lipid profile parameters as measured with the CR3000 system
1Department of General Surgery and Surgical Specialities, University of Modena and Reggio Emilia Medical School, Surgical Clinic, Modena, Italy. valeriasbl@hotmail.com
Insights
Point-of-care testing (POCT) offers faster lipid analysis for coronary heart disease (CHD) risk assessment. This method improves therapeutic turnaround times and patient outcomes by bringing testing closer to the patient.
Area of Science:
- Clinical Chemistry
- Cardiovascular Disease Diagnostics
Background:
- Elevated total cholesterol (TC) and low-density lipoprotein cholesterol (LDLC) correlate with coronary heart disease (CHD).
- Reduced high-density lipoprotein cholesterol (HDLC) also increases CHD risk.
- Increased lipid testing necessitates reliable and rapid results for risk identification and management.
Purpose of the Study:
- To evaluate the role and benefits of point-of-care testing (POCT) in lipid analysis.
- To assess the impact of POCT on diagnostic speed and patient management.
Main Methods:
- POCT brings analytical procedures closer to the patient, reducing the need for central laboratory processing.
- This approach aims to eliminate process steps, thereby shortening the time to result.
Main Results:
- POCT facilitates a shorter time to result, enabling faster management responses and improved patient outcomes.
- Benefits include enhanced therapeutic turnaround times (TATs) and reduced blood loss from decreased phlebotomy.
- POCT also contributes to diminished resource utilization in healthcare settings.
Conclusions:
- POCT provides a viable alternative to central laboratory testing for lipid profiles.
- The effectiveness of POCT relies on its analytical performance compared to central laboratory methods.
- Faster results from POCT can lead to improved clinical decision-making and patient care for cardiovascular risk.
Abstract:
Total cholesterol (TC) and low-density lipoprotein cholesterol (LDLC) levels are positively related to coronary heart disease (CHD), and high-density lipoprotein cholesterol (HDLC) levels are negatively related to CHD. Efforts to identify and treat people at increased risk based on cholesterol and lipoprotein levels have led to more lipid testing and the need for very reliable test results. Point-of-care testing (POCT) has developed from the demand for analytical information more fastly than is available from central laboratories. By carrying the analysis closer to the patient some process steps have been eliminated, facilitating a shorter time to result and faster management response with improved outcomes. Thus benefits include better therapeutic turnaround times (TATs), decreased blood loss as a result of reduced phlebotomy secondary to clinical improvement and diminished resource utilization. These effects depend on acceptable analytical performance in comparison with central laboratory techniques and in relation to clinical criteria.
